Research programme: quinolinylmethoxyaryl compounds - MerckleAlternative Names: COX-5-LOX inhibitors research programme - Merckle; Dual cyclo-oxygenase/5-lipoxygenase inhibitors research programme - Merckle
Latest Information Update: 05 Apr 2007
At a glance
- Originator Merckle
- Mechanism of Action 5-lipoxygenase inhibitors; Cyclooxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 05 Apr 2007 Discontinued - Preclinical for Inflammation in Germany (PO)
- 05 Sep 2002 This programme is still in active development
- 07 Sep 1999 New profile